Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18797315 | 1.00 | P2RX7 (0.38) | P2RX7MAPK1ALDH1A1LMNAPOLB | |
| SCHEMBL18797313 | 1.00 | P2RX7 (0.38) | P2RX7MAPK1ALDH1A1LMNAPOLB | |
| SCHEMBL18810301 | 0.81 | P2RX7 (0.33) | P2RX7MAPK1 | |
| SCHEMBL16338349 | 0.75 | P2RX7 (0.39) | P2RX7MAPK1 | |
| SCHEMBL26984379 | 0.74 | P2RX7 (0.47) | P2RX7MAPK1 | |
| SCHEMBL19984732 | 0.73 | P2RX7 (0.46) | P2RX7MAPK1 | |
| SCHEMBL18797246 | 0.72 | P2RX7 (0.39) | P2RX7MAPK1ALDH1A1LMNAPOLB | |
| SCHEMBL18797248 | 0.72 | P2RX7 (0.39) | P2RX7MAPK1ALDH1A1LMNAPOLB | |
| SCHEMBL15166664 | 0.72 | P2RX7 (0.46) | P2RX7MAPK1LMNA | |
| SCHEMBL18797582 | 0.72 | P2RX7 (0.46) | P2RX7MAPK1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3368539-B1 | SUBSTITUTED INDAZOLE COMPOUNDS AS ROR GAMMA T INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME (US) | 2020-12-02 | — | — | EP | disclosed |
| EP-3368516-B1 | SUBSTITUTED BICYCLIC PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME (US) | 2020-07-15 | — | — | EP | disclosed |
| US-10689369-B2 | Substituted indazole compounds as RORgammaT inhibitors and uses thereof | MERCK SHARP & DOHME CORP. (US) | 2020-06-23 | — | — | US | disclosed |
| US-20190276438-A1 | SUBSTITUTED INDAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME LLC | 2019-09-12 | — | — | US | disclosed |
| US-10344000-B2 | Substituted bicyclic pyrazole compounds as RORgammaT inhibitors and uses thereof | MERCK SHARP & DOHME CORP. (US) | 2019-07-09 | — | — | US | disclosed |
| US-10287272-B2 | Substituted indazole compounds as RORgammaT inhibitors and uses thereof | MERCK SHARP & DOHME CORP. (US) | 2019-05-14 | — | — | US | disclosed |
| US-20180312489-A1 | SUBSTITUTED INDAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME LLC | 2018-11-01 | — | — | US | disclosed |
| US-20180305320-A1 | SUBSTITUTED BICYCLIC PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME LLC | 2018-10-25 | — | — | US | disclosed |
| EP-3368516-A1 | SUBSTITUTED BICYCLIC PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | Merck Sharp & Dohme Corp. (US) | 2018-09-05 | — | — | EP | disclosed |
| EP-3368539-A1 | SUBSTITUTED INDAZOLE COMPOUNDS AS RORGAMMAT INHIBITORS AND USES THEREOF | Merck Sharp & Dohme Corp. (US) | 2018-09-05 | — | — | EP | disclosed |
| WO-2017075178-A1 | SUBSTITUTED BICYCLIC PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME CORP. (US) | 2017-05-04 | — | — | WO | disclosed |
| WO-2017075182-A1 | SUBSTITUTED INDAZOLE COMPOUNDS AS RORGAMMAT INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME CORP. (US) | 2017-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190276438-A1 | SUBSTITUTED INDAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | RORB, RORC, RORA | P2RX7 852/4885MAPK1 1447/4885ALDH1A1 446/4885 |
| US-20180305320-A1 | SUBSTITUTED BICYCLIC PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | RORB, RORC, RORA | P2RX7 477/4885MAPK1 1262/4885ALDH1A1 461/4885 |
| US-20180312489-A1 | SUBSTITUTED INDAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | RORB, RORC, RORA | P2RX7 737/4885MAPK1 1355/4885ALDH1A1 429/4885 |
| US-10287272-B2 | Substituted indazole compounds as RORgammaT inhibitors and uses thereof | RORB, RORC, RORA | P2RX7 746/4885MAPK1 1385/4885ALDH1A1 435/4885 |
| US-10689369-B2 | Substituted indazole compounds as RORgammaT inhibitors and uses thereof | RORB, RORC, RORA | P2RX7 852/4885MAPK1 1447/4885ALDH1A1 446/4885 |
| US-10344000-B2 | Substituted bicyclic pyrazole compounds as RORgammaT inhibitors and uses thereof | RORB, RORC, RORA | P2RX7 477/4885MAPK1 1262/4885ALDH1A1 461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.